Dating service for cancer patients

12-Jan-2020 20:44

Around half of the men diagnosed are eligible for hormone therapy, which blocks the action of male sex hormones.Abiraterone goes further and shuts down production of the hormones that fuel prostate cancer’s growth.He said: “It felt like my world fell apart overnight.The doctors explained that surgery wasn’t an option for me because the cancer had spread beyond my prostate.Adding abiraterone to ADT reduced the risk of dying over three years by 37 per cent compared with men just on ADT.It also lowered the chance of the cancer getting worse by 71 per cent compared with men just on ADT.He added: “These are the most powerful results I’ve seen from a prostate cancer trial – it’s a once-in-a-career feeling.This is one of the biggest reductions in death I’ve seen in any clinical trial for adult cancers.

He lives in Harrow with his partner and five children.

The National Institute for Health and Care Excellence (Nice), which approves drugs for the NHS, is already looking at the findings.

Professor Nicholas James, chief investigator of the trial, from the University of Birmingham, said some patients may effectively be cured while others could expect to live as long as they normally would.

Researchers say the new drug regime could “transform the treatment” of 20,000 men newly diagnosed with the disease each year in England.

Of these, 5,000 men with the most advanced disease which has spread around the body could see their life expectancy jump from 3.5 years to seven years on average.

He lives in Harrow with his partner and five children.The National Institute for Health and Care Excellence (Nice), which approves drugs for the NHS, is already looking at the findings.Professor Nicholas James, chief investigator of the trial, from the University of Birmingham, said some patients may effectively be cured while others could expect to live as long as they normally would.Researchers say the new drug regime could “transform the treatment” of 20,000 men newly diagnosed with the disease each year in England.Of these, 5,000 men with the most advanced disease which has spread around the body could see their life expectancy jump from 3.5 years to seven years on average.After three years, fewer than 5 per cent of those on abiraterone whose disease was confined had relapsed and got worse compared to 25 per cent in the ADT arm of the trial.